11 December 2018 - - US-based clinical stage biotechnology company Moderna, Inc. (NASDAQ: MRNA) has priced its initial public offering of 26,275,993 shares of common stock at a public offering price of USD 23.00 per share, before underwriting discounts and commissions, the company said.

Moderna's common stock began trading on The NASDAQ Global Select Market on 7 December under the ticker symbol "MRNA."

All of the common stock is being offered by Moderna. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Moderna, are expected to be USD 604.3m, excluding any exercise of the underwriters' option to purchase additional shares.

Morgan Stanley, Goldman Sachs and Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. BofA Merrill Lynch, Barclays Capital Inc. and Piper Jaffray and Co. are acting as book-running managers for the offering. Oddo BHF SCA, Oppenheimer and Co. Inc., Needham and company, LLC and Chardan are acting as co-managers for the offering.

Moderna is in the discovery and development of messenger RNA therapeutics and vaccines to direct the body's cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.